The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.K. Competition Watchdog Accuses Merck of Obstructing Biosimilars

U.K. Competition Watchdog Accuses Merck of Obstructing Biosimilars

May 23, 2017 • By Ben Hirschler

  • Tweet
  • Email
Print-Friendly Version / Save PDF

It argues that the discounts in question meant infliximab was competitively priced and offered savings to the U.K. National Health Service, without hindering competition.

You Might Also Like
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Biosimilars to Raise Unique Questions

Tuesday’s statement of objections from the CMA sets out its provisional views and does not mean there has in fact been any breach of competition law.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The CMA will carefully consider any representations by the company under investigation before determining whether the law has been infringed,” it says in a statement.

The CMA has been increasingly active in pharmaceuticals.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In December last year, it fined Pfizer a record 84.2 million pounds ($109 million) for its role in ramping up the cost of an epilepsy drug. In February 2016, it fined GlaxoSmithKline 37.6 million pounds over deals delaying the launch of generic copies of its antidepressant Seroxat (paroxetine).

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biosimilar, infliximab, International, Legal, Merck & Co, Remicade, REMICADE (infliximab), U.K.

You Might Also Like:
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Biosimilars to Raise Unique Questions
  • As Biosimilars Hit, EU Pharma Warns against Blanket Prescribing

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.